Amsacrine

Amsacrine
Clinical data
ATC code	L01XX01 (WHO) ;
Legal status
Legal status	US: a;
Pharmacokinetic data
Protein binding	96 to 98%
Elimination half-life	8–9 hours
Identifiers
	IUPAC name N-(4-(acridin-9-ylamino)-3-methoxyphenyl)methanesulfonamide;
CAS Number	51264-14-3 ;
PubChem CID	2179;
DrugBank	DB00276 ;
ChemSpider	2094 ;
UNII	00DPD30SOY;
KEGG	D02321 ;
ChEBI	CHEBI:2687 ;
ChEMBL	ChEMBL43 ;
CompTox Dashboard (EPA)	DTXSID4022604 ;
ECHA InfoCard	100.051.887
Chemical and physical data
Formula	C21H19N3O3S
Molar mass	393.46 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=S(=O)(Nc1ccc(c(OC)c1)Nc2c4c(nc3c2cccc3)cccc4)C;
	InChI InChI=1S/C21H19N3O3S/c1-27-20-13-14(24-28(2,25)26)11-12-19(20)23-21-15-7-3-5-9-17(15)22-18-10-6-4-8-16(18)21/h3-13,24H,1-2H3,(H,22,23) ; Key:XCPGHVQEEXUHNC-UHFFFAOYSA-N ;
	(verify)

Amsacrine (synonyms: m-AMSA, acridinyl anisidide) is an antineoplastic agent.

^ Horstmann MA, Hassenpflug WA, zur Stadt U, Escherich G, Janka G, Kabisch H (December 2005). "Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children". Haematologica. 90 (12): 1701–3. PMID 16330449.

Clinical data

ATC code	L01XX01 (WHO)
Legal status
Legal status	US: a
Pharmacokinetic data
Protein binding	96 to 98%
Elimination half-life	8–9 hours
Identifiers
IUPAC name N-(4-(acridin-9-ylamino)-3-methoxyphenyl)methanesulfonamide
CAS Number	51264-14-3^Y
PubChem CID	2179
DrugBank	DB00276^Y
ChemSpider	2094^Y
UNII	00DPD30SOY
KEGG	D02321^Y
ChEBI	CHEBI:2687^Y
ChEMBL	ChEMBL43^Y
CompTox Dashboard (EPA)	DTXSID4022604
ECHA InfoCard	100.051.887
Chemical and physical data
Formula	C₂₁H₁₉N₃O₃S
Molar mass	393.46 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES O=S(=O)(Nc1ccc(c(OC)c1)Nc2c4c(nc3c2cccc3)cccc4)C
InChI InChI=1S/C21H19N3O3S/c1-27-20-13-14(24-28(2,25)26)11-12-19(20)23-21-15-7-3-5-9-17(15)22-18-10-6-4-8-16(18)21/h3-13,24H,1-2H3,(H,22,23)^Y Key:XCPGHVQEEXUHNC-UHFFFAOYSA-N^Y
(verify)